|Mr. Ian D. Page||CEO, MD & Exec. Director||N/A||N/A||56|
|Mr. Richard John Cotton BA Hons, FCMA||CFO & Director||381k||N/A||56|
|Dr. Anthony Gerard Griffin||MD of Dechra Veterinary Products for Europe & Exec. Director||N/A||N/A||54|
|Ms. Katy Clough||Group HR Director||N/A||N/A||N/A|
|Mr. Mike Eldred BA, MBA||Pres of North America||N/A||N/A||47|
Dechra Pharmaceuticals plc develops, manufactures, sells, and markets veterinary pharmaceuticals and related products for veterinarians worldwide. The company operates through the European Pharmaceuticals, the North American Pharmaceuticals, and the Pharmaceuticals Research and Development segments. It offers various endocrinology, dermatology and care, anesthesia and analgesia, cardiovascular disease, ophthalmology, and equine medicine products; food producing animal antimicrobials; poultry vaccines; and pet diets. The company markets and distributes veterinary pharmaceuticals and equipment; provides financial services; and manufactures human and veterinary pharmaceutical products for third party customers. Dechra Pharmaceuticals plc markets its products through wholesaler and distributor networks. The company was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Dechra Pharmaceuticals plc’s ISS Governance QualityScore as of September 1, 2017 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 7.